Medicare Enrolled
Dr. Brian Shimkus, MD
Medical Oncology · Georgetown, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Shimkus from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shimkus? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shimkus
Dr. Brian Shimkus is a medical oncology in Georgetown, TX, with 20 years in practice. Based on federal Medicare data, Dr. Shimkus performed 33,212 Medicare services across 2,000 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shimkus received a total of $30,457 from 110 pharmaceutical and/or device companies across 1327 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shimkus is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 28% volume in TX$ $30,457 industry payments
Medicare Practice Summary
Medicare Utilization ↗33,212
Medicare services
Top 28% in TX for medical oncology
2,000
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,661 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 11,520 | $19 | $63 |
| Pembrolizumab injection (Keytruda) | 7,800 | $44 | $155 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,948 | $19 | $170 |
| Iron infusion (Monoferric) | 2,500 | $16 | $74 |
| Flow cytometry, additional marker | 1,564 | $18 | $159 |
| Office visit, established patient, complex (40-54 min) | 1,233 | $126 | $508 |
| Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 1,219 | $34 | $170 |
| Blood draw (venipuncture) | 719 | $8 | $9 |
| Dexamethasone injection (steroid) | 710 | $0 | $1 |
| Complete blood count (CBC) with differential | 471 | $8 | $27 |
| Anti-nausea injection (Aloxi/palonosetron) | 300 | $1 | $41 |
| Drug injection, under skin or into muscle | 258 | $10 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 235 | $22 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 224 | $96 | $422 |
| Office visit, established patient (30-39 min) | 209 | $89 | $348 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 208 | $69 | $210 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 131 | $25 | $134 |
| Injection, diphenhydramine hcl, up to 50 mg | 124 | $1 | $4 |
| Administration of chemotherapy into vein, each additional hour | 114 | $21 | $163 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 100 | $48 | $207 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 98 | $130 | $609 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 97 | $16 | $65 |
| Injection of additional new drug or substance into vein | 79 | $12 | $66 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 79 | $3 | $13 |
| Flow cytometry technique for dna or cell analysis, first marker | 69 | $49 | $269 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 59 | $1 | $7 |
| New patient office visit, complex (60-74 min) | 35 | $151 | $634 |
| Telephone medical discussion with physician, 21-30 minutes | 33 | $75 | $329 |
| Drawing of blood for a medical problem | 27 | $65 | $293 |
| Administration of additional new drug or substance into vein, 1 hour or less | 25 | $49 | $206 |
| Urinalysis, manual | 12 | $3 | $12 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $66 | $231 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
8.8% high complexity
77.0% medium
14.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$30,457
Total received (2018-2024)
Avg $4,351/year across 7 years
Top 27% in TX for medical oncology
110
Companies
1,327
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$25,232 (82.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,865 (9.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,061 (6.8%)
Other
Charitable contributions, space rental, and other categories
$299 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,292
2023$4,721
2022$4,063
2021$7,116
2020$2,738
2019$3,984
2018$3,542
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
EMD Serono, Inc.
$2,823
Janssen Biotech, Inc.
$2,415
Novartis Pharmaceuticals Corporation
$1,886
Pharmacosmos Therapeutics Inc.
$1,556
E.R. Squibb & Sons, L.L.C.
$1,360
Amgen Inc.
$1,329
AstraZeneca Pharmaceuticals LP
$1,290
PFIZER INC.
$1,138
Genentech USA, Inc.
$779
Merck Sharp & Dohme Corporation
$772
Celgene Corporation
$726
Incyte Corporation
$695
Merck Sharp & Dohme LLC
$639
Astellas Pharma US Inc
$593
GENZYME CORPORATION
$588
Lilly USA, LLC
$540
Eisai Inc.
$508
Takeda Pharmaceuticals U.S.A., Inc.
$426
Seagen Inc.
$380
Seattle Genetics, Inc.
$359
GlaxoSmithKline, LLC.
$340
Regeneron Healthcare Solutions, Inc.
$314
Ipsen Biopharmaceuticals, Inc
$303
Puma Biotechnology, Inc.
$303
NOVARTIS PHARMACEUTICALS CORPORATION
$299
BeiGene USA, Inc.
$270
EISAI INC.
$269
Myriad Genetic Laboratories, Inc.
$263
COMSORT, Inc
$250
Pharmacyclics LLC, An AbbVie Company
$227
MorphoSys, US Inc.
$227
ARRAY BIOPHARMA INC
$227
Kite Pharma, Inc.
$217
Gilead Sciences, Inc.
$214
Karyopharm Therapeutics Inc.
$205
Bayer HealthCare Pharmaceuticals Inc.
$202
Octapharma USA, Inc.
$194
Boehringer Ingelheim Pharmaceuticals, Inc.
$186
SANOFI-AVENTIS U.S. LLC
$178
Alexion Pharmaceuticals, Inc.
$177
PUMA BIOTECHNOLOGY, INC.
$169
AVEO Pharmaceuticals, Inc.
$160
Rigel Pharmaceuticals, Inc.
$159
TAIHO ONCOLOGY, INC.
$157
Janssen Scientific Affairs, LLC
$150
Taiho Oncology, Inc.
$143
Genmab U.S., Inc.
$141
ASD Specialty Healthcare, LLC
$141
ABBVIE INC.
$140
Bayer Healthcare Pharmaceuticals Inc.
$136
AMAG Pharmaceuticals, Inc.
$125
Sobi, Inc
$123
Kyowa Kirin, Inc.
$122
PharmaEssentia USA Corporation
$120
TerSera Therapeutics LLC
$113
Foundation Medicine, Inc.
$112
Daiichi Sankyo Inc.
$108
JAZZ PHARMACEUTICALS INC.
$99
Stemline Therapeutics Inc.
$96
Dova Pharmaceuticals
$95
ADC Therapeutics America, Inc.
$95
Secura Bio, Inc.
$94
Heron Therapeutics, Inc.
$88
TESARO, Inc.
$80
Adaptive Biotechnologies Corporation
$76
Helsinn Therapeutics (U.S.), Inc.
$70
Organon LLC
$69
Mirati Therapeutics, Inc.
$69
Global Blood Therapeutics, Inc.
$67
Deciphera Pharmaceuticals Inc.
$67
Blueprint Medicines Corporation
$66
Agios Pharmaceuticals, Inc.
$65
CTI BioPharma Corp.
$63
Teva Pharmaceuticals USA, Inc.
$62
AbbVie, Inc.
$61
Exelixis Inc.
$59
SERVIER PHARMACEUTICALS LLC
$58
Jazz Pharmaceuticals Inc.
$58
SOBI, INC
$58
Verastem, Inc.
$57
Aveo Pharmaceuticals, Inc.
$48
Organon Llc
$47
Mylan Institutional Inc.
$45
G1 Therapeutics, Inc.
$43
Epizyme, Inc.,
$42
Sysmex Inostics Inc
$41
Pharmacyclics LLC, an AbbVie Company
$38
Spectrum Pharmaceuticals Inc.
$38
Olympus America Inc.
$38
Coherus Biosciences Inc.
$38
Apellis Pharmaceuticals, Inc.
$36
Menarini Silicon Biosystems, Inc.
$31
AbbVie Inc.
$24
Azurity Pharmaceuticals, Inc.
$23
Sun Pharmaceutical Industries Inc.
$22
EUSA Pharma (US) LLC
$22
Sumitomo Pharma America, Inc.
$19
Sandoz Inc.
$19
Advanced Accelerator Applications
$19
MACROGENICS, INC.
$18
Allergan Inc.
$18
Servier Pharmaceuticals LLC
$17
Blue Earth Diagnostics Limited
$17
Boston Scientific Corporation
$16
Acrotech Biopharma LLC
$15
Sirtex Medical Inc
$15
Tempus AI, Inc
$14
Myovant Sciences Inc.
$13
TG THERAPEUTICS, INC.
$13
Janssen Pharmaceuticals, Inc
$9
Top 3 companies account for 23.4% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALOXI · ALUNBRIG · AUGTYRO · AVYCAZ · AYVAKIT · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · Axumin · BALVERSA · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CALQUENCE · CINVANTI · COPIKTRA · COSELA · CUVITRU · CYRAMZA · Cabometyx · Cellsearch · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EMEND · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · FARESTON · FARYDAK · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · FULPHILA · Fabhalta · GAZYVA · GILOTRIF · HEMADY · HERZUMA · Halaven · Herceptin · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · IMLYGIC · INJECTAFER · INLYTA · INQOVI · INREBIC · Idhifa · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MARGENZA · MEKINIST · MONJUVI · MVASI · MYLOTARG · MYRISK · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · Poteligeo · Prolia · QINLOCK · Quzyttir · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · SANCUSO · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUTENT · Somatuline Depot · Stivarga · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tepmetko · TheraSphere Y90 Glass Microspheres 10 GBq · Tibsovo · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VIVIMUSTA · VONJO · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vonjo · Vyloy · WELIREG · XALKORI · XOSPATA · XPOVIO · XTANDI · XYNTHA · Xermelo · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZARXIO · ZEJULA · ZEPZELCA · ZYKADIA · Zoladex · clonoSEQ · iTIND System · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (83%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $92 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
15
Per 100K population
2.3
County median income
$108,309
Nearest hospital
ROCK SPRINGS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Shimkus is a mixed practice specialist, with above-average Medicare volume (top 28% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Shimkus experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Shimkus performed 11,520 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shimkus receive payments from pharmaceutical companies?
Yes. Dr. Shimkus received a total of $30,457 from 110 companies across 1,327 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shimkus's costs compare to other medical oncologys in Georgetown?
Dr. Shimkus's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shimkus) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Georgetown
Browse medical oncologys in Georgetown ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology